Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV–hepatitis C virus coinfected patients

Abstract

Low 25(OH)D levels may impair virologic response to PEGIFN + RBV therapy, especially in difficult-to-treat patients. Vitamin D supplementation should be considered and evaluated prospectively in HIV-HCV coinfected patients receiving CHC treatment.